Axsome Therapeutics, Inc. (AXSM) fair value analysis
Nasdaq · Updated 2026-10-19
AXSM price how computed
Valuation status
Awaiting full valuationAXSM's estimate rests on a sector-average price-to-earnings multiple, not on its own validated earnings history.
TickrTrends does not publish a borrowed multiple as a verdict. A verdict publishes automatically once AXSM's own trailing P/E history validates; every covered stock is re-evaluated weekly.
- Last price
- $157.14
- Sector
- Healthcare
- 12-month range
- $129.55–$255.17
- Market cap
- $8.23B
- From 52-week high
- -38.4%
- Shares outstanding
- 52.4M
- Rank in Healthcare by quality score
- #194 of 301
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Axsome Therapeutics, Inc. is a biopharmaceutical company that develops and commercializes novel therapies for central nervous system disorders, including depression, migraine, and other neurological conditions. The company operates in the United States and conducts research and development activities to bring new treatment options to market.
AXSM currently ranks #194 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $8.23B
- P/E (trailing)
- n/m
- Revenue (TTM)
- $777M
- Net margin
- -24.7%
- EPS (TTM)
- $-3.75
- Gross margin
- 93.8%
- Debt / equity
- 2.63
- Revenue growth (3-yr avg)
- 92.6%
- Shares outstanding
- 52.4M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Expanding
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 13 · oversold
- 50-day average
- $197.94
- 200-day average
- $200.58
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-11-02 (pre-market)
- Last 8 quarters vs consensus
- 4 beat, 3 missed
- Quarter by quarter
- 2026-06 ▬ met (0.0%)
2026-03 ▼ miss (-46.5%)
2025-12 ▲ beat (+22.8%)
2025-09 ▼ miss (-4.4%)
2025-06 ▲ beat (+11.0%)
2025-03 ▲ beat (+9.6%)
2024-12 ▼ miss (-53.6%)
2024-09 ▲ beat (+4.8%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 21 buy · 1 hold · 0 sell (22 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $283
- Target vs last price
- +80.1%
What our data shows for AXSM
- Shares are trading in the lower third of their 12-month price range of $129.55–$255.17.
- The 14-day relative strength index sits at an oversold 13.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- AXSM's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent AXSM news
TickrTrends' derived news-sentiment signal for AXSM is currently leaning positive, computed from recent coverage.
- Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2 (manilatimes.net, 2026-10-07)
- AXSM Maintained by Deutsche Bank -- Price Target Lowered to $267 (gurufocus.com, 2026-09-29)
- AXSM Maintains Buy Rating by Truist Securities -- Price Target Raised to $285 (gurufocus.com, 2026-09-23)
What people are saying
Follow the AXSM conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — TickrTrends' derived indicators for AXSM show a shift in the 50/200-day trend state this week, moving from mixed to downtrend. The current valuation verdict remains awaiting full valuation. This change in trend state reflects altered momentum characteristics in the Healthcare sector stock this week.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for AXSM showed a shift in the Relative Strength Index this week, moving from neutral territory into oversold zone. The Healthcare sector stock remains under a valuation verdict of awaiting full valuation based on available analysis.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is AXSM stock undervalued?
AXSM's estimate rests on a sector-average price-to-earnings multiple rather than its own validated earnings history, and TickrTrends does not publish a borrowed multiple as a verdict. It is re-evaluated every week.
What is AXSM's TickrTrends verdict?
AXSM is currently marked 'Awaiting full valuation' - a verdict publishes automatically once AXSM's own trailing P/E history validates under our standards.
How does AXSM compare to other Healthcare stocks?
AXSM ranks #194 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is AXSM overbought or oversold?
AXSM's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does AXSM report earnings next?
AXSM's next earnings report is scheduled for 2026-11-02 (pre-market), per the published earnings calendar.
Does AXSM usually beat earnings estimates?
Over its last 8 reported quarters AXSM beat the consensus estimate 4 times and missed 3 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about AXSM?
Of 22 analysts covering AXSM, 21 rate it a buy, 1 a hold and 0 a sell - buy-leaning, with a consensus price target of $283 (+80.1% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.